

Remarks

Claims 1-13 and 15 are pending in the application. Applicant would like to thank Examiner for allowing Claims 1-12. Applicant has cancelled pending claims 13 and 15.

§112 Rejections

I. Claims 13 and 15 were rejected under 35 USC §112, 2nd paragraph as being indefinite.

Examiner asserts that Claims 13 is a reach through claim. Applicant would like to remind Examiner that "reach through claims" is an European standard and not a US standard. Applicant maintains, as discussed in the previous office action response, that those skilled in the art would be fully aware of compounds that meet the limitations of the combination claim. However, in order to expedite the application to allowance, Applicant has cancelled Claim 13 without prejudice and without admitting any acquiescence to Examiner's assertion.

Examiner also asserts that "feeding disorders" is not defined. Applicant respectfully disagrees. The types of feeding disorders is clearly outlined on page 2, line 10 – line 11. "Hence, agents capable of blocking NPY binding at these receptor subtype(s) should have utility in a number of feeding disorders including obesity, anorexia nervosa, bulimia nervosa;...." In addition, Applicant maintains their position with respect to Claim 15 (as outlined in the previous office action response) that the specification is fully supportive for all of the indications listed in Claim 15 based on the knowledge in the art. Nevertheless, in order to expedite the application to allowance, Applicant has cancelled Claim 15 without prejudice and without acquiescing to Examiner's assertion.

Applicant respectfully submits that the application is in condition for allowance and requests a prompt notice of allowance.

Respectfully Submitted:

Date: January 19, 2005

Arlene K. Musser
Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871